EXPERIENCE OF USING BEDAQUILINE IN THE MULTIMODALITY THERAPY OF TUBERCULOSIS PATIENTS WITH CONCURRENT HIV INFECTION
The goal of the study: to evaluate efficiency and safety of the anti-tuberculosis drug of bedaquiline in the multimodality therapy of patients with HIV-associated tuberculosis with multiple/extensive drug resistance (MDR/XDR).Materials and methods. 14 patients were treated with the regimens containi...
Main Author: | |
---|---|
Format: | Article |
Language: | Russian |
Published: |
New Terra Publishing House
2017-10-01
|
Series: | Туберкулез и болезни лёгких |
Subjects: | |
Online Access: | https://www.tibl-journal.com/jour/article/view/1045 |
_version_ | 1797696721088675840 |
---|---|
author | G. S. BALASANYANTS |
author_facet | G. S. BALASANYANTS |
author_sort | G. S. BALASANYANTS |
collection | DOAJ |
description | The goal of the study: to evaluate efficiency and safety of the anti-tuberculosis drug of bedaquiline in the multimodality therapy of patients with HIV-associated tuberculosis with multiple/extensive drug resistance (MDR/XDR).Materials and methods. 14 patients were treated with the regimens containing bedaquiline. The majority of patients (12; 85.7%) received antiretroviral therapy. 11 (78.6%) patients were diagnosed with the generalized form of tuberculosis affecting two organs and more. All 14 patients were infectious: 2 had MDR TB and 12 had XDR TB, and of them, 11 had XDR TB with resistance to 8-10 anti-tuberculosis drugs.Results. 12 out of 14 patients completed the intensive phase with administration of bedaquiline. By the end of the first month of treatment intoxication symptoms disappeared in 50.0% of patients, and by the end of the second month, they remitted in 83.5%. The positive X-ray changes were observed in 50% of patients, and they manifested through the partial resolution of focal infiltrate changes in the lungs. Cessation of bacillary excretion was documented by the end of the second month in 6 patients, by the end of the 3rd month in 1 patient, by the end of the 6th month in 3 patients, totally in 10 out of 12 patients (83.3%). During treatment, all patients had an electrocardiogram, and none of them had prolongation of QT interval. |
first_indexed | 2024-03-12T03:30:23Z |
format | Article |
id | doaj.art-f2620ac4fbdb4b7ab4719e8871fe79fd |
institution | Directory Open Access Journal |
issn | 2075-1230 2542-1506 |
language | Russian |
last_indexed | 2024-03-12T03:30:23Z |
publishDate | 2017-10-01 |
publisher | New Terra Publishing House |
record_format | Article |
series | Туберкулез и болезни лёгких |
spelling | doaj.art-f2620ac4fbdb4b7ab4719e8871fe79fd2023-09-03T13:29:12ZrusNew Terra Publishing HouseТуберкулез и болезни лёгких2075-12302542-15062017-10-01959495410.21292/2075-1230-2017-95-9-49-541045EXPERIENCE OF USING BEDAQUILINE IN THE MULTIMODALITY THERAPY OF TUBERCULOSIS PATIENTS WITH CONCURRENT HIV INFECTIONG. S. BALASANYANTS0Военно-медицинская академия им. С. М. КироваThe goal of the study: to evaluate efficiency and safety of the anti-tuberculosis drug of bedaquiline in the multimodality therapy of patients with HIV-associated tuberculosis with multiple/extensive drug resistance (MDR/XDR).Materials and methods. 14 patients were treated with the regimens containing bedaquiline. The majority of patients (12; 85.7%) received antiretroviral therapy. 11 (78.6%) patients were diagnosed with the generalized form of tuberculosis affecting two organs and more. All 14 patients were infectious: 2 had MDR TB and 12 had XDR TB, and of them, 11 had XDR TB with resistance to 8-10 anti-tuberculosis drugs.Results. 12 out of 14 patients completed the intensive phase with administration of bedaquiline. By the end of the first month of treatment intoxication symptoms disappeared in 50.0% of patients, and by the end of the second month, they remitted in 83.5%. The positive X-ray changes were observed in 50% of patients, and they manifested through the partial resolution of focal infiltrate changes in the lungs. Cessation of bacillary excretion was documented by the end of the second month in 6 patients, by the end of the 3rd month in 1 patient, by the end of the 6th month in 3 patients, totally in 10 out of 12 patients (83.3%). During treatment, all patients had an electrocardiogram, and none of them had prolongation of QT interval.https://www.tibl-journal.com/jour/article/view/1045туберкулезсочетанный с вич-инфекциейтуберкулез с множественной лекарственной устойчивостью возбудителябедаквилинпрекращение бактериовыделенияэффективность лечения |
spellingShingle | G. S. BALASANYANTS EXPERIENCE OF USING BEDAQUILINE IN THE MULTIMODALITY THERAPY OF TUBERCULOSIS PATIENTS WITH CONCURRENT HIV INFECTION Туберкулез и болезни лёгких туберкулез сочетанный с вич-инфекцией туберкулез с множественной лекарственной устойчивостью возбудителя бедаквилин прекращение бактериовыделения эффективность лечения |
title | EXPERIENCE OF USING BEDAQUILINE IN THE MULTIMODALITY THERAPY OF TUBERCULOSIS PATIENTS WITH CONCURRENT HIV INFECTION |
title_full | EXPERIENCE OF USING BEDAQUILINE IN THE MULTIMODALITY THERAPY OF TUBERCULOSIS PATIENTS WITH CONCURRENT HIV INFECTION |
title_fullStr | EXPERIENCE OF USING BEDAQUILINE IN THE MULTIMODALITY THERAPY OF TUBERCULOSIS PATIENTS WITH CONCURRENT HIV INFECTION |
title_full_unstemmed | EXPERIENCE OF USING BEDAQUILINE IN THE MULTIMODALITY THERAPY OF TUBERCULOSIS PATIENTS WITH CONCURRENT HIV INFECTION |
title_short | EXPERIENCE OF USING BEDAQUILINE IN THE MULTIMODALITY THERAPY OF TUBERCULOSIS PATIENTS WITH CONCURRENT HIV INFECTION |
title_sort | experience of using bedaquiline in the multimodality therapy of tuberculosis patients with concurrent hiv infection |
topic | туберкулез сочетанный с вич-инфекцией туберкулез с множественной лекарственной устойчивостью возбудителя бедаквилин прекращение бактериовыделения эффективность лечения |
url | https://www.tibl-journal.com/jour/article/view/1045 |
work_keys_str_mv | AT gsbalasanyants experienceofusingbedaquilineinthemultimodalitytherapyoftuberculosispatientswithconcurrenthivinfection |